Mistura Informatics Limited® was launched in 2011 by Professor Steve Bazire MBE and Dawn Price, both highly revered throughout the world of Pharmacy. Their main aim was to develop and deliver a wide r ...
Piramal Enterprises’ Critical Care Division expands its product portfolio; enters into an agreement to acquire Janssen's injectable anesthesia and pain management products20 Oct 2017
The potential acquisition is in line with the Group's strategy to boost growth in the healthcare businesses, both organically and inorganically
October 10, 2016, Mumbai: Piramal Enterprises (NSE: PEL, BSE: 500302) announced that its wholly owned Critical Care subsidiary in the UK has entered into an agreement to acquire five anesthesia and pain management injectable products from Janssen Pharmaceutica NV. The products to be acquired are five injectable versions of well-established Janssen brands, Sublimaze (fentanyl citrate), Sufenta (sufentanil citrate), Rapifen (alfentanil hydrochloride), Dipidolor (piritramide), and Hypnomidate (etomidate) (the “Products”).
Piramal has agreed to acquire the brand names and all related IP as associated with the Products, including the know-how to make both the active pharmaceutical ingredients (“API”) and the finished dosage forms of the Products. The Products are currently marketed in over 50 countries.
For further information on the financials, please visit our website: www.piramal.com
ANALYTICS ENGINES SUCCESSFULLY COMPLETE SBRI PHASE I
Belfast, September 29, 2017– The Small Business Research Initiative for Medicines Optimisation launched by the Department of Health (DoH) and Department for Economy (DfE) in Northern Ireland have approved PRECISION for Pharmacy for deployment at Western Health NHS Trust.
Pharmacy staff optimization solution to be developed by Belfast-based big data analytics firm
Belfast, March 31, 2017– ANALYTICS ENGINES have won an SBRI (Small Business Research Initiative) competition to develop and deliver a staff optimization tool to streamline hospital pharmacy operations and ensure patient safety around medicines reconciliation.
Piramal Enterprises Completes the Acquisition of a Portfolio of Drugs for Spasticity and Pain Management from Mallinckrodt LLC.20 Mar 2017
Mumbai – Piramal Enterprises Limited (“Piramal,” NSE: PEL, BSE: 500302) announced that its wholly owned Critical Care subsidiary in the UK has completed its acquisition of a portfolio of drugs for spasticity and pain management from Mallinckrodt LLC (“Mallinckrodt”).
The portfolio acquired includes Gablofen® (baclofen), a severe spasticity management product, which is currently marketed in the United States, and two pain management products, which are currently under development. Gablofen® has also been approved for launch in eight European markets. Gablofen® is the only intrathecal baclofen drug available in vials and pre-filled syringes, which are preferred by users over the competing products available in ampoules. The pain management drugs under development are also for intrathecal administration.
For further information on the financials, please visit our website: www.piramal.com:
14 Feb 2020 Labcold LtdLabcold IntelliCold pharamcy range now feature a touch screen controller and two temperature probes for improved cold chain storage.